The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and ...

In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrilla ...

Study suggests a path forward for device therapy, though caveats are plenty ...

Boston Scientific (NYSE:BSX) announced new findings from the CHAMPION-AF trial supporting its Watchman FLX system.

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

Medicare typically covers Watchman surgery under Part A (hospital insurance) if deemed medically necessary for reducing stroke risk in patients with non-valvular atrial fibrillation. Coverage often ...